Similarly, the CDK9 inhibitor AZ5576 efficiently targeted DLBCL cells expressing high MYC level in vitro and in vivo, and its effects were potentiated by enforcing MYC expression [236]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.